GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhonghong Pulin Medical Products Co 300981.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

15.72

+2.14%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.37bn

FY2016FY2025

Net income

−CN¥112.4m

FY2016FY2025

Free cash flow

−CN¥186.9m

FY2016FY2025

Shareholders' equity

CN¥5.26bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.37bnCN¥2.46bnCN¥2.11bnCN¥1.57bnCN¥4.91bnCN¥4.78bnCN¥1.17bnCN¥967.5mCN¥951.2mCN¥710.1m
Gross profitCN¥487.8mCN¥273.8mCN¥98.3mCN¥18.9mCN¥2.88bnCN¥3.38bnCN¥219.3mCN¥165.8mCN¥180.4mCN¥124.0m
Research and developmentCN¥51.1mCN¥49.7mCN¥31.6mCN¥8.8mCN¥21.8mCN¥11.6mCN¥9.3mCN¥9.2mCN¥1.9mCN¥1.4m
Operating income−CN¥53.3m−CN¥65.7m−CN¥136.9m−CN¥11.0mCN¥2.79bnCN¥3.19bnCN¥106.2mCN¥70.4mCN¥86.3mCN¥48.3m
Net income−CN¥112.4m−CN¥87.1m−CN¥130.9mCN¥66.9mCN¥2.34bnCN¥2.66bnCN¥89.3mCN¥56.7mCN¥65.0mCN¥38.2m
Diluted earnings per share-0.27-0.19-0.320.155.478.280.260.450.200.12

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥7.44bnCN¥7.23bnCN¥7.06bnCN¥6.82bnCN¥7.15bnCN¥3.67bnCN¥1.08bnCN¥974.9mCN¥697.7mCN¥628.9m
Cash and short-term investments—CN¥2.33bnCN¥2.93bnCN¥3.03bnCN¥4.41bnCN¥1.56bnCN¥71.0mCN¥31.7mCN¥66.1mCN¥66.4m
Total liabilitiesCN¥2.02bnCN¥1.61bnCN¥1.14bnCN¥684.1mCN¥597.6mCN¥1.12bnCN¥608.3mCN¥598.8mCN¥377.8mCN¥373.6m
DebtCN¥218.8mCN¥730.3mCN¥492.1mCN¥67.1mCN¥17.2mCN¥107.4mCN¥329.6mCN¥302.5mCN¥170.0mCN¥174.3m
Shareholders' equityCN¥5.26bnCN¥5.47bnCN¥5.77bnCN¥6.12bnCN¥6.55bnCN¥2.56bnCN¥467.7mCN¥378.2mCN¥321.2mCN¥256.7m
Shares outstanding423m459m410m447m428m322m342m125m324m322m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥3.7mCN¥183.9mCN¥140.7mCN¥106.7mCN¥2.36bnCN¥2.72bnCN¥184.4mCN¥23.8mCN¥96.0mCN¥102.4m
Capital spending−CN¥190.6m−CN¥107.4m−CN¥103.2m−CN¥207.7m−CN¥960.6m−CN¥429.4m−CN¥150.5m−CN¥203.1m−CN¥78.1m−CN¥61.7m
Free cash flow−CN¥186.9mCN¥76.5mCN¥37.5m−CN¥100.9mCN¥1.40bnCN¥2.29bnCN¥33.9m−CN¥179.3mCN¥17.9mCN¥40.7m
Dividends paid−CN¥126.5m−CN¥215.9m−CN¥294.6m−CN¥500.0m−CN¥250.0m−CN¥575.0m−CN¥19.8m−CN¥14.0m−CN¥8.6m−CN¥61.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥876.4mCN¥601.9mCN¥509.5mCN¥626.1mCN¥608.4mCN¥629.1mCN¥618.4mCN¥689.8m
Gross profitCN¥268.2mCN¥86.1mCN¥68.2mCN¥73.2mCN¥39.1mCN¥84.0mCN¥37.4mCN¥140.2m
Operating incomeCN¥192.8mCN¥13.9m−CN¥18.8m−CN¥15.6m−CN¥17.5mCN¥22.7m−CN¥129.0mCN¥21.5m
Net incomeCN¥153.7mCN¥4.9m−CN¥105.2m−CN¥13.0m−CN¥13.2mCN¥18.9m−CN¥138.2mCN¥18.5m
Diluted earnings per share0.360.01-0.25-0.03-0.030.04-0.300.04
Cash from operations———−CN¥44.0m−CN¥20.0mCN¥10.0m—CN¥116.0m
Capital spending−CN¥4.0m−CN¥21.0m−CN¥70.0m−CN¥100.0m−CN¥12.0m−CN¥7.0m−CN¥40.0m−CN¥15.0m
Free cash flow———−CN¥144.0m−CN¥32.0mCN¥3.0m—CN¥101.0m
Total assetsCN¥7.69bnCN¥7.79bnCN¥7.44bnCN¥7.65bnCN¥7.61bnCN¥7.43bnCN¥7.23bnCN¥7.39bn
Cash and short-term investments———CN¥2.64bnCN¥2.59bnCN¥2.69bnCN¥2.33bnCN¥2.70bn
DebtCN¥180.8mCN¥119.6mCN¥218.8mCN¥1.11bnCN¥1.22bnCN¥901.8mCN¥721.7mCN¥565.8m
Shareholders' equityCN¥5.26bnCN¥5.26bnCN¥5.26bnCN¥5.37bnCN¥5.38bnCN¥5.49bnCN¥5.47bnCN¥5.62bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin11.1%11.1%4.7%1.2%58.7%70.7%—
Operating margin-3.9%-1.7%-5.8%3.4%56.7%67.2%—
Net margin-4.7%-3.5%-6.2%4.3%47.7%55.7%—
Return on equity-2.1%-1.6%-2.3%1.1%35.7%104.2%—
Return on assets-1.5%-1.2%-1.9%1.0%32.7%72.5%—
Free cash flow yield2.0%2.8%2.6%3.1%33.7%42.6%—
Revenue growth-3.4%16.7%33.9%-68.0%2.7%308.1%—
Earnings growth29.0%-33.4%-295.6%-97.1%-12.1%2883.8%—
Current ratio2.68x3.70x5.19x6.90x9.21x2.42x—
Debt to equity0.04x0.13x0.08x0.01x—0.03x0.70x
Equity ratio70.7%75.7%81.7%89.8%91.6%69.6%—
Interest coverage-3.00x-1.59x-7.33x16.88x879.15x312.44x—
R&D as a share of sales2.2%2.0%1.5%0.6%0.4%0.2%—
Buybacks as a share of market value8.0%-12.0%8.1%-4.3%-33.1%6.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue14.7%-13.1%14.7%
Operating income69.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin15.8%10.3%39.3%35.3%
Operating margin-2.5%-3.1%31.4%26.9%
Net margin-4.1%-3.1%26.1%22.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-47.2-67.8-50.296.46.3
Price to sales2.22.43.14.13.0

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 27 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021
Paid in the year0.350.250.4550.6362.0980.583
  • 1-to-1 reverse split · 27 Jun 2025
  • 13-for-10 split · 26 May 2023
  • 9-for-5 split · 30 May 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.